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Abstract
Objective—To examine the associations between hormonal contraceptive use and measures of 
HIV disease progression and antiretroviral treatment (ART) effectiveness.
Study design—A prospective cohort study of women with prevalent HIV infection in St. 
Petersburg, Russia, was conducted. After contraceptive counseling, participants chose to use 
combined oral contraceptives (COCs), depot-medroxyprogesterone acetate (DMPA), a copper 
intrauterine device (IUD) or male condoms for pregnancy prevention. Among participants not 
using ART at enrollment, we used multivariate Cox regression to assess the association between 
current (time-varying) contraceptive use and disease progression, measured by the primary 
composite outcome of CD4 decline to <350 cells/mm3, ART initiation or death. Among 
participants using ART at enrollment, we used linear mixed models to estimate the predicted mean 
CD4 change at select time points by contraceptive method.
Results—During a total of 5233 months follow-up among participants not using ART with 
enrollment CD4 ≥ 350 cells/mm3 (n=315), 97 experienced disease progression. Neither current 
use of COCs [adjusted hazard ratio (aHR) 0.91, 95% confidence interval (CI) 0.56–1.48] nor 
DMPA (aHR 1.28, 95% CI 0.71–2.31) was associated with a statistically significant increased risk 
for disease progression compared with use of nonhormonal methods (IUD or condoms). Among 
participants using ART at enrollment (n=77), we found no statistically significant differences in 
the predicted mean changes in CD4 cell count comparing current use of COCs (p=.1) or DMPA 
(p=.3) with nonhormonal methods.
Conclusion—Hormonal contraceptive use was not significantly associated with measures of 
HIV disease progression or ART effectiveness among women with prevalent HIV infection.
☆The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the 
Centers for Disease Control and Prevention.
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Implications—Hormonal contraceptive use was not significantly associated with measures of 
HIV disease progression or ART effectiveness among women with prevalent HIV infection.
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1. Introduction
Preventing unintended pregnancy among women with HIV reduces vertical transmission 
and yields additional health and social benefits for women, children and families. Hormonal 
contraception, including oral contraceptives (OCs) and injectable methods, are widely 
available in many countries with high HIV prevalence and are highly effective at preventing 
pregnancy when used consistently and correctly. However, there are theoretical concerns 
that hormonal contraception may hasten HIV disease progression by altering immunologic 
responses [1]. While a randomized controlled trial among postpartum HIV-infected women 
reported an association between hormonal contraceptive use and accelerated HIV disease 
progression compared with copper intrauterine device (IUD) use [2], observational studies 
report no evidence of an association [3,4]. All previous studies were conducted in settings 
where antiretroviral treatment (ART) was unavailable or recommended only for those with 
advanced disease [3,4]. A recent increase in ART availability as well as guidelines 
expanding the population for whom ART is recommended has introduced new complexity 
to the study of hormonal contraception and HIV disease progression [3] and suggests the 
need for further study.
In 2013, World Health Organization (WHO) recommended that national HIV programs 
provide ART to all people with HIV with CD4 ≤ 500 cells/mm3, with priority given to those 
with severe disease or CD4 ≤ 350 cells/mm3 [5]. As a result, it may be useful to reexamine 
the issue of hormonal contraceptive use among women with HIV in settings where ART is 
more widely provided than in previous studies and using different definitions of disease 
progression than those previously used, which included outcomes such as CD4 <200 or 250 
cells/mm3, clinical AIDS or death. These outcomes will become rarer with earlier and more 
wide-spread ART initiation; thus, it will be valuable to examine disease progression using 
outcomes more applicable to settings with increased ART availability and use. Additionally, 
as the number of HIV-infected women taking ART increases, it will be important to 
examine the effect of hormonal contraception on ART effectiveness. Currently, there is a 
limited body of evidence examining the association between hormonal contraception and 
ART effectiveness, including studies examining women on established ART [6] and 
initiating ART [7,8], none of which reports evidence of a detrimental effect of hormonal 
contraception on ART effectiveness. We sought to expand knowledge about the safety of 
hormonal contraception for women with HIV by examining the associations between 
hormonal contraception and measures of HIV disease progression and ART effectiveness 
among a cohort of HIV-infected women in St. Petersburg, Russia, where ART was available 
and recommended more broadly than in previous studies.
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2. Materials and methods
2.1. Study population and procedures
Participants in this study were enrolled in a project examining the integration of family 
planning services into HIV clinical care in St. Petersburg, Russia [9]. Participants were 
recruited between October, 2007, and October, 2011, from three sites providing routine care 
to HIV-infected women. Eligible participants were aged 16–45 years with confirmed HIV 
infection; sexually active in the last year; not pregnant, breastfeeding or intending to 
breastfeed; and desired to avoid pregnancy for ≥ 12 months. Women were ineligible if they 
had a hysterectomy, were sterile or had used hormonal contraception or an IUD in the past 3 
months.
Candidate participants received counseling on all approved contraceptive methods in Russia 
and on condom use for prevention of HIV transmission. Study contraceptive methods 
included combined oral contraceptives (COCs; 30 mcg ethinyl estradiol/150 mcg 
desogestrel), depot-medroxyprogesterone acetate (DMPA), copper IUD (copper surface area 
of 375 mm2) and male condoms. If women were interested in using any study contraceptive 
method for pregnancy prevention (COCs, DMPA, copper IUD or male condoms alone), 
study clinicians assessed their medical eligibility for all study methods using WHO guidance 
[10]. All women were eligible to use male condoms. Women interested in participating 
selected a study method from among those they were medically eligible to use. 
Contraceptive methods were provided free of charge during the study. All participants were 
given male condoms. The study was approved by the institutional review boards of the 
Centers for Disease Control and Prevention and the collaborating institutions in Russia. All 
participants provided written informed consent.
After enrollment, scheduled study visits occurred at 6 weeks and every 6 months thereafter 
for 18–48 months. Participants were encouraged to return at any time for physical 
complaints or suspected pregnancy and could switch contraceptive methods at any time. At 
enrollment and scheduled visits, participants underwent physical exams, provided biologic 
specimens (to measure CD4 cell counts and plasma HIV-1 RNA) and were interviewed to 
collect demographic, reproductive and behavioral information (biologic specimens were 
routinely collected at the 6-week visit until March, 2009). Laboratory testing was conducted 
at the St. Petersburg City AIDS Center central laboratory. CD4 cell counts were performed 
using FACSCalibur (BD Biosciences, San Jose, CA). Plasma HIV-1 RNA (viral load) levels 
were quantified using the Abbott RealTime HIV-1 Assay (Abbott Molecular Inc., Des 
Plaines, IL), with 150 copies per milliliter as the lower limit of detection. Urine pregnancy 
tests were performed at study visits and self-reported pregnancies were verified by medical 
record review. Women who became pregnant were referred for care and were no longer 
followed. Deaths were ascertained through clinic, hospital and vital records and reports from 
family or friends. Two physician investigators (DMK and DJJ) blinded to participant 
contraceptive use classified each death as likely attributable to AIDS, non-AIDS death, 
indeterminate or unknown [11]. Non-AIDS deaths were not considered in our analyses.
At each follow-up visit, participants were asked about their contraceptive use since their last 
visit. Staff recorded the dispensing of study contraceptive methods. Participants were also 
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asked about ART use and responses were verified using medical records, when available. At 
the time of the study, government-funded antiretroviral drugs were available in Russia and 
ART was generally initiated in patients with CD4 <350 cells/mm3. All analyses were 
conducted separately by ART use at enrollment.
2.2. Statistical analysis
2.2.1. Participants not using ART at enrollment—Participants were eligible for 
inclusion in analyses if they had CD4 measurements at ≥ 1 follow-up visit. We examined 
three composite outcome measures to assess disease progression. The first (primary) 
outcome was examined among participants with enrollment CD4 ≥ 350 cells/mm3 and was 
defined as the first occurrence of CD4 decline to <350 cells/mm3, ART initiation or death. 
The second outcome was examined among all participants eligible for analyses and was 
defined as the first occurrence of a CD4 decline of ≥ 20% from enrollment or death. The 
third outcome was examined among participants with enrollment CD4 ≥ 200 cells/mm 3 and 
was defined as the first occurrence of CD4 decline to <200 cells/mm3 or death.
We used Cox proportional hazards models to examine the associations between 
contraceptive use and these HIV disease progression outcomes. Participants were censored 
at pregnancy (all outcomes) or at ART initiation (second and third outcomes). For our 
primary analysis, we examined contraceptive use as a time-varying exposure, wherein a 
participant who switched methods could contribute person time to multiple contraceptive 
groups. As method switching could be related to disease progression (e.g., if women who 
become more ill due to HIV discontinued hormonal contraception), we also examined 
contraceptive use defined as the method chosen at enrollment. Under this definition, a 
participant is categorized under the method they chose at enrollment, even if they switched 
to other methods. Because few women chose the IUD, we considered IUD use and condom 
use together as nonhormonal method use. Models were adjusted for enrollment CD4 count, 
age, postpartum status and prior hormonal contraceptive use. The addition of other 
enrollment variables to the model, including time since HIV diagnosis, ever use of ART, 
time since ART use, viral load, marital status, frequency of condom use, positive sexually 
transmitted disease (STD) test, parity, recent intravenous drug use or abortion history, did 
not appreciably change the adjusted hazard ratio (aHR) estimates. For each model, the 
proportional hazards assumption was confirmed for the included variables by examining 
interaction terms with time.
2.2.2. Participants using ART at enrollment—Participants were eligible for inclusion 
in analyses if they used their ART regimen at enrollment for ≥ 3 months and had CD4 
measurements at ≥ 1 follow-up visit while using ART. We used linear mixed models 
without assuming independence of CD4 measurements in each participant to estimate the 
predicted mean change in CD4 count by contraceptive method at select time points. 
Participants were censored at the first occurrence of pregnancy, death or ART 
discontinuation. We assumed a linear change in CD4 count during follow-up. Models were 
adjusted for enrollment CD4 count, duration of ART use at enrollment, whether or not the 
ART regimen was highly active antiretroviral therapy (HAART) and time under observation 
in the study. HAART was defined as regimens including two nucleoside reverse 
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transcriptase inhibitors and one protease inhibitor (PI) or one nonnucleoside reverse 
transcriptase inhibitor (NNRTI). We examined contraceptive use defined both as current 
(time-varying) use and as method chosen at enrollment.
We also examined the proportion of participants who were virally suppressed on ART at 
enrollment who remained in that state during follow-up, by contraceptive method chosen at 
enrollment. Viral suppression was defined as viral load <150 copies per milliliters.
3. Results
Of 760 women eligible for the study, 709 enrolled. Three women were later discontinued 
from the study due to unrecognized pregnancy at enrollment. Of the remaining 706 women 
enrolled, 545 were not using ART at enrollment and 161 were using ART.
3.1. Participants not using ART at enrollment
Of 545 participants not using ART at enrollment, 426 (78%) had ≥ 1 follow-up CD4 
measurement and were eligible for inclusion in analyses. Among these participants, median 
follow-up time was 19 (interquartile range, 11–30) months. At enrollment, 183 chose to use 
COCs, 87 chose DMPA and 156 chose a nonhormonal method (33 chose the IUD and 123 
chose condoms) (Table 1). The median enrollment CD4 count was higher among those 
choosing DMPA and COCs than among those choosing a nonhormonal method. Compared 
to women choosing nonhormonal methods, a higher percentage of women choosing DMPA 
or COCs previously used ART, were postpartum, previously used hormonal contraception 
and had a positive STD test at enrollment. A higher percentage of women choosing DMPA 
as compared to other methods had ≥ 2 live births, while a higher percentage of those 
choosing nonhormonal methods reported always using condoms. Of those who reported 
using ART in the past month (n=105), all had a delivery in the past month and none reported 
using ART prior to their pregnancy, suggesting that previous use of ART in the study 
sample was primarily for the prevention of perinatal transmission. During follow-up, 103 
participants switched their contraceptive method at least once and 63 participants became 
pregnant.
We examined the primary composite outcome of CD4 decline to <350 cells/mm3, ART 
initiation or death among participants with enrollment CD4 ≥ 350 cells/mm3 (n=315). 
Among these participants, 97 experienced at least one event: 61 experienced only a CD4 
count decline, 18 experienced a CD4 count decline and initiated ART, 11 only initiated 
ART, 6 died as their only event and 1 experienced a CD4 count decline and died. The hazard 
of experiencing an event did not significantly differ among those currently using COCs 
[aHR 0.91, 95% confidence interval (CI) 0.56–1.48] or DMPA (aHR 1.28, 95% CI 0.71–
2.31) compared to those using nonhormonal methods (Table 2). Results were similar when 
we defined contraceptive exposure as method selected at enrollment (Table 2).
We also examined the composite outcome of a decline of ≥ 20% from enrollment CD4 count 
or death. Among all women not using ART at enrollment with ≥ 1 follow-up CD4 
measurement (n=426), 203 experienced events: 194 experienced only a CD4 count decline, 
8 experienced death as their only event and 1 experienced a CD4 count and died. The hazard 
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of experiencing any event did not significantly differ among those currently using COCs 
(aHR 0.85, 95% CI 0.61–1.18) or DMPA (aHR 1.14, 95% CI 0.77–1.71) compared to those 
using nonhormonal methods (Table 2). Results were similar when we defined contraceptive 
exposure based on method selected at enrollment (Table 2).
Among women whose enrollment CD4 was ≥ 200 cells/mm3 (n=402), we examined the 
outcome of CD4 decline to <200 cells/mm3 or death (results not shown). Twenty-four 
participants experienced events; 17 experienced only a CD4 count decline and 7 experienced 
a CD4 count decline and death. When examining this outcome, there was no significant 
association with current use of COCs (aHR 0.65, 95% CI 0.25–1.70) or DMPA (aHR 0.99, 
95% CI 0.31–3.20) compared to use of nonhormonal methods. Results were similar when 
we defined contraceptive exposure as method selected at enrollment.
For all analyses, results were similar when IUD use was excluded from the referent group. 
Additionally, results were similar among subgroups defined by previous use of ART, 
previous use of hormonal contraception and postpartum status.
3.2. Participants using ART at enrollment
Of 161 participants using ART at enrollment, 77 had at ≥ 1 follow-up CD4 measurement 
while using ART and had been on their regimen for ≥ 3 months and were thus eligible for 
inclusion in analyses. These participants contributed 308 CD4 measurements during a 
median follow-up of 23 (interquartile range 14–31) months. The majority of participants 
(90%) were on a HAART regimen. At enrollment, 24 of these participants chose to use 
COCs, 17 chose DMPA and 36 chose a nonhormonal method (9 chose the IUD and 27 chose 
condoms) (Table 3). At enrollment, a higher percentage of those choosing nonhormonal 
methods used ART >6 months and reported always using condoms than those choosing 
DMPA or COCs. During follow-up, 19 participants switched their contraceptive method at 
least once, 5 participants became pregnant and 2 participants died.
When adjusting for CD4 cell count at enrollment, duration of ART use at enrollment, 
HAART regimen and time under observation, we found no statistically significant 
differences in the predicted mean changes in CD4 cell count when comparing current use of 
COCs (p=.1) or DMPA (p=.3) with nonhormonal methods (Table 4). Similarly, when 
defining contraceptive exposure as the method selected at enrollment, we found no 
statistically significant differences in the predicted mean changes in CD4 cell count when 
comparing COCs (p=.7) or DMPA (p=.3) with nonhormonal methods.
Among participants choosing COCs at enrollment, 23 were virally suppressed at enrollment 
of whom 20 (87%) remained suppressed during follow-up. Among participants choosing 
DMPA at enrollment, 12 were virally suppressed at enrollment of whom 10 (83%) remained 
suppressed. Among participants choosing a nonhormonal method at enrollment, 29 were 
virally suppressed at enrollment of whom 24 (83%) remained suppressed.
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In our study of women with prevalent HIV infection in St. Petersburg, Russia, we did not 
find a statistically significant association between hormonal contraceptive use and measures 
of HIV disease progression among women not taking ART. Our results are consistent with 
previous cohort studies examining both incident [12–15] and prevalent [4,15–20] HIV cases, 
none of which reported an association between hormonal contraceptive use and accelerated 
HIV disease progression, as measured by CD4 <200 or 250 cells/mm3, ART initiation, 
clinical AIDS, death or change in CD4 count or viral load. Only one study has reported an 
association between hormonal contraception and HIV disease progression. A randomized 
controlled trial among postpartum HIV-infected women in Zambia reported an association 
between hormonal contraceptive use (OCs and DMPA) and accelerated HIV disease 
progression (CD4 decline to <200 cells/mm3, ART initiation or death) compared with 
copper IUD use [2]. However, interpretation of these findings is complicated by the 
potential biases introduced by high rates of method switching and high and differential rates 
of loss to follow-up by method assignment. Our study differs from previous investigations in 
the setting and outcomes studied. Whereas other studies were conducted in settings where 
ART was unavailable or only recommended for those with advanced disease, in our study 
population, ART was available and was initiated using broader criteria. Because of this, we 
included CD4 count decline to <350 cells/mm3 as an outcome, rather than progression to 
clinical AIDS. As a result, our findings may be more applicable to settings with expanded 
access to ART, which will become more common given recent recommendations [5].
While we were limited by the small number of women using ART at enrollment in our 
study, we did not find evidence to indicate that hormonal contraceptive use had a 
detrimental effect on ART effectiveness. The interpretation of our findings may be 
complicated by variation in ART regimens and duration of use. Nonetheless, our findings 
are consistent with the limited body of evidence examining the association between 
hormonal contraception and ART effectiveness. A prospective cohort study of women on 
established ART found no difference in the estimated trend in CD4 cell count over time 
between implant users and nonhormonal users [6]. Two additional studies examined the use 
of hormonal contraception among women initiating ART. One found no association between 
DMPA and ART failure (detectable viral load, regimen change or death) [7], while the other 
one found no differences between hormonal contraceptive users (OCs, injectable 
contraceptive or implants) and nonusers on CD4 count or viral load response [8]. Current 
WHO guidance states that, in general, women taking ART are eligible to use all hormonal 
contraceptive methods, but special consideration may be necessary with certain ART 
regimens (particularly some NNRTIs and ritonavir-boosted PIs), as pharmacokinetic data 
suggest a potential reduction in the effectiveness of some hormonal contraceptives when 
taken with these regimens [21]. As more women with HIV will have access to ART, it will 
be important to clarify these issues.
The strengths of our study include use of time-varying contraceptive measures and the 
ability to verify self-reported contraceptive use with dispensing logs. Also, the start of study 
follow-up coincided with contraceptive method initiation, minimizing the influence of recent 
hormonal contraceptive use. Additionally, our sample included women seeking HIV 
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services who wished to use contraception, which may better reflect real-world scenarios than 
studies including women choosing to not use contraception. Finally, our findings were 
robust when we examined multiple definitions of exposure and outcome.
Our study has several limitations. Participants had prevalent HIV infection, and while we 
adjusted for enrollment CD4 cell count, we cannot rule out residual confounding related to 
disease stage or duration. Contraceptive methods were self-selected, and while we attempted 
to control for participant characteristics related to method choice [9] or other differences 
between method groups at enrollment, residual confounding may remain. There may be 
misclassification in some outcomes we examined, as an event may have occurred based on a 
single follow-up CD4 measurement. As CD4 counts can be variable [22], some events may 
represent clinically inconsequential fluctuations. Additionally, ART was not provided as 
part of the study; thus, we cannot be sure that standard criteria were used to initiate ART. 
Finally, as our sample was a convenience sample of women seeking HIV clinical services in 
one city, the generalizability of our findings to other populations may be limited.
Safe, effective options to prevent unintended pregnancy are a necessity for women with 
HIV. Our results are consistent with findings of most previous studies that hormonal 
contraceptive use is not associated with accelerated disease progression among women with 
HIV not using ART. In addition, our results and those of previous studies suggest that the 
use of hormonal contraception by women with HIV concurrently using ART is not 
associated with changes in ART effectiveness; however, the evidence addressing this 
question is quite limited. As eligibility and access to ART are expanded, more women of 
reproductive age will be using ART, making it increasingly important to understand the 
effects of simultaneous use of hormonal contraception and ART on the effectiveness of both 
drugs.
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Table 1
Characteristics of women with prevalent HIV infection not using ART at enrollment, by contraceptive method 
selected.
COCs (N=183) DMPA (N=87) Nonhormonala (N=156)
Enrollment CD4 count (cells/mm3): median, IQRb 545, 342–753 606, 379–807 456, 319–599
Enrollment log10 HIV RNA: median, IQRb 3, 2–4 3, −1 −3 4, 3–4
Previously used ARTc 76 (41.5) 58 (66.7) 41 (26.3)
Use of ART within the past monthc,d 51 (27.9) 43 (49.4) 11 (7.0)
Time since HIV diagnosisc
 <1 year 74 (40.4) 33 (37.9) 40 (25.6)
 1–2 years 28 (15.3) 16 (18.4) 28 (18.0)
 >2 years 81 (44.3) 38 (43.7) 88 (56.4)
Age (years)
 16–24 67 (36.6) 33 (37.9) 50 (32.1)
 25–29 84 (45.9) 30 (34.5) 68 (43.6)
 30–45 32 (17.5) 24 (27.6) 38 (24.4)
Married or nonmarital union 149 (81.4) 71 (81.6) 131 (84.0)
Previous abortionc
 Yes 105 (57.4) 55 (63.2) 98 (62.8)
 No 51 (27.9) 31 (35.6) 45 (28.9)
 Never pregnant 27 (14.8) 1 (1.2) 13 (8.3)
Previous live births c
 0 53 (29.0) 4 (4.6) 40 (25.6)
 1 102 (55.7) 50 (57.5) 91 (58.3)
 ≥2 28 (15.3) 33 (37.9) 25 (16.0)
Postpartum (≤6 weeks)c 85 (46.5) 54 (62.1) 36 (23.1)
Prior hormonal contraception usec 73 (39.9) 33 (37.9) 32 (20.5)
Frequency of condom usec
 Always 61 (33.3) 15 (17.2) 81 (51.9)
 Rarely/sometimes/almost always 99 (54.1) 57 (65.5) 70 (44.9)
 Never 23 (12.6) 15 (17.2) 5 (3.2)
Multiple partners in previous year 18 (9.8) 9 (10.3) 16 (10.3)
Positive STD test at enrollmentc,e 12 (6.6) 11 (12.6) 5 (3.2)
Use of intravenous drugs in the past 3 monthsc 6 (3.3) 15 (17.2) 5 (4.1)
Data are shown as number (percentage) unless otherwise indicated.
ART, antiretroviral therapy; IQR, interquartile range.
a
Includes participants choosing the copper IUD (n=33) and condoms (n=123).
bp<.05, Wilcoxon rank sum test.
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cp<.05, chi-squared test.
d
Data on timing of ART use missing for n=17 (COC), n=12 (DMPA) and n=17 (nonhormonal).
eChlamydia or gonorrhea.
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Table 2
Association between contraceptive method use and measures of HIV disease progression among women with 
prevalent HIV infection not using ART at enrollment.
Time to CD4 count decline to <350 cells/mm3,
ART initiation or deatha
Time to CD4 count decline ≥20% or deathb
Events Person-months at risk HRc 95% CI Events Person-months at risk HRc 95% CI
Current contraceptive method (time-varying)d
 COCs 31 2194 0.91 0.56–1.48 85 2219 0.85 0.61–1.18
 DMPA 17 882 1.28 0.71–2.31 45 782 1.14 0.77–1.71
 Nonhormonal 49 2247 1.00 Ref 73 2131 1.00 Ref
Contraceptive method at enrollment
 COCs 32 2246 0.91 0.56–1.47 79 2265 0.82 0.58–1.16
 DMPA 20 1106 1.27 0.71–2.26 53 881 1.23 0.82–1.85
 Nonhormonal 45 1996 1.00 Ref 64 2032 1.00 Ref
ART, antiretroviral therapy; HR, hazard ratio.
a
Time to first occurrence of CD4 count decline to <350 cells/mm3, ART initiation or death among participants with enrollment CD4 counts ≥350 
cells/ mm3 and ≥1 follow-up CD4 measurement (n=315).
b
Time to first occurrence of CD4 count decline to ≥20% of enrollment CD4 count or death among all participants with ≥1 follow-up CD4 
measurement (n=426).
cAdjusted for CD4 count at enrollment, postpartum status, prior hormonal contraceptive use and age.
d
If a method switch occurred between two CD4 measurements, the previous method was censored at the date of the last CD4 measurement before 
the switch.
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Table 3
Characteristics of women with prevalent HIV infection using ART at enrollment, by contraceptive method 
selected.
COCs (N=24) DMPA (N=17) Nonhormonala (N=36)
Enrollment CD4 count (cells/mm3): median, IQR 305, 213–420 430, 319–493 351, 252–449
Viral suppression at enrollment (HIV RNA ≤150 copies per milliliter) 23 (95.8) 12 (70.6) 29 (80.6)
HAART regimen 22 (91.7) 15 (88.2) 32 (88.9)
Months on ARTb
 3–6 months 8 (33.3) 11 (64.7) 7 (19.4)
 7–12 months 6 (25.0) 3 (17.7) 10 (27.8)
 >12 months 10 (41.7) 3 (17.7) 19 (52.8)
Time since HIV diagnosis
 <1 year 3 (12.5) 1 (5.9) 2 (5.6)
 1–2 years 4 (16.7) 1 (5.9) 7 (19.4)
 >2 years 17 (70.8) 15 (88.2) 27 (75.0)
Age (years)
 16–24 9 (37.5) 5 (29.4) 3 (8.3)
 25–29 9 (37.5) 7 (41.2) 18 (50.0)
 30–45 6 (25.0) 5 (29.4) 15 (41.7)
Married or nonmarital union 20 (83.3) 14 (82.4) 30 (83.3)
Previous abortion
 Yes 13 (54.2) 12 (70.6) 27 (75.0)
 No 7 (29.2) 5 (29.4) 6 (16.7)
 Never pregnant 4 (16.7) 0 (0.0) 3 (8.3)
Previous live births
 0 10 (41.7) 1 (5.9) 9 (25.0)
 1 12 (50.0) 11 (64.7) 21 (58.3)
 >2 2 (8.3) 5 (29.4) 6 (16.7)
Postpartum (≤6 weeks) 5 (20.8) 8 (47.1) 8 (22.2)
Prior hormonal contraception use 11 (45.8) 3 (17.7) 8 (22.2)
Frequency of condom usec
 Always 6 (25.0) 6 (35.3) 22 (61.1)
 Rarely/sometimes/almost always 16 (66.7) 7 (41.2) 14 (38.9)
 Never 2 (8.3) 4 (23.5) 0 (0.0)
Multiple partners in previous year 3 (12.5) 0 (0.0) 3 (8.3)
Positive STD test at enrollmentd 2 (8.3) 1 (5.9) 0 (0.0)
Use of intravenous drugs in the past 3 monthsc 1 (4.2) 2 (11.8) 0 (0.0)
Data are shown as number (percentage) unless otherwise indicated.
Statistical tests of significant differences were based on Kruskal–Wallis test, chi-squared test or Fisher’s Exact Test, as appropriate. ART, 
antiretroviral therapy; IQR, interquartile range.
a
Includes participants choosing the copper IUD (n=9) and condoms (n=27).
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bp<.05, chi-squared test.
cp<.05, Fisher’s Exact Test.
dChlamydia or gonorrhea.
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Table 4
Predicted mean change in CD4 cell count at 6, 12 and 18 months among women with prevalent HIV infection 
using ART at enrollment, by contraceptive method.
Predicted mean change in CD4 cell count, cells/mm3 (95% CI)a p Value (vs.
nonhormonal)
6 months 12 months 18 months
Current contraceptive method (time-varying)
 COCs 83.2 (23.0–143.4) 106.0 (47.8–164.2) 128.8 (68.9–188.7) 0.1
 DMPA 83.8 (8.5–159.2) 106.6 (33.5–179.8) 129.4 (55.7–203.2) 0.3
 Nonhormonal 45.9 (−10.3 to 102.0) 68.7 (14.0–123.3) 91.4 (34.5–148.4)
Contraceptive method at enrollment
 COCs 52.7 (−12.2 to 117.6) 85.4 (24.2–146.7) 118.2 (56.9–179.6) 0.7
 DMPA 80.3 (4.7–155.9) 113.1 (41.5–184.7) 145.8 (75.0–216.6) 0.3
 Nonhormonal 39.9 (−15.8 to 95.7) 72.7 (20.1–125.4) 105.5 (51.6–159.3)
ART, antiretroviral therapy.
aAdjusted for CD4 cell count at enrollment, duration of ART use at enrollment (months), HAART regimen (yes/no) and time under observation in 
the study.
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